These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 35371982)
1. Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas. Vuong HG; Ngo TNM; Le HT; Jea A; Hrachova M; Battiste J; McNall-Knapp R; Dunn IF Front Oncol; 2022; 12():858148. PubMed ID: 35371982 [TBL] [Abstract][Full Text] [Related]
2. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. Vuong HG; Le HT; Ngo TNM; Fung KM; Battiste JD; McNall-Knapp R; Dunn IF J Neurooncol; 2021 Dec; 155(3):225-234. PubMed ID: 34796414 [TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. Vuong HG; Ngo TNM; Le HT; Dunn IF J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633 [TBL] [Abstract][Full Text] [Related]
4. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study. Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G Front Oncol; 2020; 10():795. PubMed ID: 32582540 [No Abstract] [Full Text] [Related]
5. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant. Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837 [TBL] [Abstract][Full Text] [Related]
6. H3K27M and Osada Y; Saito R; Shibahara I; Sasaki K; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T Neurooncol Adv; 2021; 3(1):vdab038. PubMed ID: 34013205 [TBL] [Abstract][Full Text] [Related]
7. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847 [TBL] [Abstract][Full Text] [Related]
8. Risk stratification of H3 K27M-mutant diffuse midline gliomas based on anatomical locations: an integrated systematic review of individual participant data. Vuong HG; Le HT; Jea A; McNall-Knapp R; Dunn IF J Neurosurg Pediatr; 2022 Jul; 30(1):99-106. PubMed ID: 35535848 [TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases]. Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644 [No Abstract] [Full Text] [Related]
10. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848 [TBL] [Abstract][Full Text] [Related]
11. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993 [TBL] [Abstract][Full Text] [Related]
12. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker. Agarwal P; Aiyer HM Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633 [TBL] [Abstract][Full Text] [Related]
13. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance? Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407 [TBL] [Abstract][Full Text] [Related]
16. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Schulte JD; Buerki RA; Lapointe S; Molinaro AM; Zhang Y; Villanueva-Meyer JE; Perry A; Phillips JJ; Tihan T; Bollen AW; Pekmezci M; Butowski N; Oberheim Bush NA; Taylor JW; Chang SM; Theodosopoulos P; Aghi MK; Hervey-Jumper SL; Berger MS; Solomon DA; Clarke JL Neurooncol Adv; 2020; 2(1):vdaa142. PubMed ID: 33354667 [TBL] [Abstract][Full Text] [Related]
17. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis. Lu VM; Alvi MA; McDonald KL; Daniels DJ J Neurosurg Pediatr; 2019 Mar; 23(3):308-316. PubMed ID: 30544362 [TBL] [Abstract][Full Text] [Related]
18. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101 [TBL] [Abstract][Full Text] [Related]
19. Primary spinal cord gliomas: Pathologic features associated with prognosis. Tanaka Y; Natsumeda M; Ohashi M; Saito R; Higa N; Akahane T; Hashidate H; Ito J; Fujii S; Sasaki A; Tanimoto A; Hanaya R; Watanabe K; Oishi M; Kawashima H; Kakita A J Neuropathol Exp Neurol; 2024 Dec; 83(12):1010-1019. PubMed ID: 39074166 [TBL] [Abstract][Full Text] [Related]
20. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors. Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]